-- European equities traded in the US as American depositary receipts began the week little changed late Monday morning, edging 0.02% higher to 1,822.16 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and telecommunications company Nokia (NOK), which advanced 26% and 9.3%, respectively. They were followed by furniture maker Natuzzi (NTZ) and biotech firm Evaxion (EVAX), which climbed 7.1% and 3.4%, respectively.
The decliners from continental Europe were led by accommodations booking company trivago (TRVG) and brewing company Anheuser-Busch InBev (BUD), which dropped 3.3% and 1.2%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and lender Banco Santander (SAN), which were off 0.9% and 0.8%, respectively.
The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Mereo BioPharma Group (MREO), which rose 7% and 4.8%, respectively. They were followed by biopharmaceutical companies NuCana (NCNA) and Bicycle Therapeutics (BCYC), which increased 4.1% and 2.4%, respectively.
The decliners from the UK and Ireland were led by biotech company Trinity Biotech (TRIB) and cruise line operator Carnival (CUK), which fell 4.7% and 3.3%, respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and lender Barclays (BCS), which were down 2.2% and 0.9%, respectively.